A detailed history of Janus Henderson Group PLC transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Janus Henderson Group PLC holds 4,896,166 shares of RNA stock, worth $156 Million. This represents 0.12% of its overall portfolio holdings.

Number of Shares
4,896,166
Previous 3,656,843 33.89%
Holding current value
$156 Million
Previous $149 Million 50.54%
% of portfolio
0.12%
Previous 0.08%

Shares

10 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$37.21 - $48.14 $46.1 Million - $59.7 Million
1,239,323 Added 33.89%
4,896,166 $225 Million
Q2 2024

Aug 14, 2024

BUY
$22.73 - $40.85 $54.9 Million - $98.6 Million
2,414,010 Added 194.23%
3,656,843 $149 Million
Q1 2024

May 15, 2024

BUY
$9.16 - $25.52 $11.1 Million - $31.1 Million
1,216,730 Added 4661.26%
1,242,833 $31.7 Million
Q4 2023

Feb 14, 2024

SELL
$4.87 - $9.37 $185 - $356
-38 Reduced 0.15%
26,103 $236,000
Q3 2023

Nov 14, 2023

BUY
$6.3 - $11.35 $132 - $238
21 Added 0.08%
26,141 $166,000
Q2 2023

Aug 14, 2023

SELL
$10.62 - $17.34 $382 - $624
-36 Reduced 0.14%
26,120 $289,000
Q1 2023

May 15, 2023

BUY
$15.35 - $25.65 $401,494 - $670,901
26,156 New
26,156 $401,000
Q4 2020

Feb 16, 2021

SELL
$24.73 - $35.12 $4.46 Million - $6.34 Million
-180,446 Closed
0 $0
Q3 2020

Nov 16, 2020

SELL
$23.35 - $35.94 $3.34 Million - $5.15 Million
-143,157 Reduced 44.24%
180,446 $5.08 Million
Q2 2020

Aug 14, 2020

BUY
$26.62 - $31.5 $8.61 Million - $10.2 Million
323,603 New
323,603 $9.15 Million

Others Institutions Holding RNA

About Avidity Biosciences, Inc.


  • Ticker RNA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 52,127,000
  • Market Cap $1.66B
  • Description
  • Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...
More about RNA
Track This Portfolio

Track Janus Henderson Group PLC Portfolio

Follow Janus Henderson Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.